Nicotinic and dopamine D2 receptors mediate nicotine-induced changes in ventral tegmental area neurotensin system.
Neuropeptides have been implicated in the psychopathology of stimulants of abuse. Neurotensin is a neuropeptide associated with the regulation of the nigrostriatal and mesolimbic dopamine pathways. In addition, the ventral tegmental area, a midbrain region implicated in the rewarding effects of most, if not all, addictive drugs, appears to be a particularly critical target for nicotine action. Because neurotensin has been linked with both mesolimbic and mesocortical dopamine function, we examined the impact of nicotine treatment on central nervous neurotensin systems by measuring changes in neurotensin tissue content because it has been shown that such changes reflect alterations in release and activity of this peptide system. Male Sprague-Dawley rats received multiple administrations of (+/-) nicotine 4.0 mg/kg/day (0.8 mg/kg, i.p.; 5 x 2-h intervals) in the presence or absence of selective dopamine receptor antagonists (dopamine D(1); SCH 23390 or dopamine D(2); eticlopride) or two doses of the non-selective nicotinic acetylcholine receptor antagonist (mecamylamine; 3.0 and 6.0 mg/kg, s.c.). The nicotine treatment significantly decreased neurotensin-like immunoreactivity content in the ventral tegmental area, as well as related regions such as prefrontal cortex, substantia nigra, and anterior striatal region 12-18 h after drug treatment, but not the nucleus accumbens. The nicotine-mediated decrease in the neurotensin-like immunoreactivity of the ventral tegmental area was selectively blocked by a specific dopamine D(2), but not a dopamine D(1), receptor antagonist, while mecamylamine attenuated at the low (3.0 mg/kg) and completely blocked at high (6.0 mg/kg) dose this nicotine effect. These findings with previous studies, suggest that nicotine-mediated dopamine release activates D(2) receptors which in turn increases neurotensin release, turnover and acutely reduces tissue levels in the ventral tegmental area and other limbic and basal ganglia structures.
Alburges
Mario E
ME
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA. mario.alburges@utah.edu
Hoonakker
Amanda J
AJ
Hanson
Glen R
GR
D000818:Animals; D001479:Basal Ganglia / Q000187:drug effects / Q000502:physiology; D001552:Benzazepines / Q000008:administration & dosage / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects / Q000502:physiology; D065127:Dopamine D2 Receptor Antagonists; D004305:Dose-Response Relationship, Drug; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D008297:Male; D008464:Mecamylamine / Q000008:administration & dosage / Q000494:pharmacology; D009479:Neuropeptides / Q000502:physiology; D009496:Neurotensin / Q000502:physiology*; D009538:Nicotine / Q000008:administration & dosage / Q000494:pharmacology*; D018733:Nicotinic Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D017397:Prefrontal Cortex / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors / Q000502:physiology; D017448:Receptors, Dopamine D2 / Q000502:physiology*; D012457:Salicylamides / Q000008:administration & dosage / Q000494:pharmacology; D013681:Tegmentum Mesencephali / Q000187:drug effects* / Q000502:physiology
D001552:Benzazepines; D065127:Dopamine D2 Receptor Antagonists; D009479:Neuropeptides; D018733:Nicotinic Antagonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D012457:Salicylamides; C031644:neurotensin-like immunoreactivity; D009496:Neurotensin; D008464:Mecamylamine; D009538:Nicotine; C045989:eticlopride
Neuropharmacology. 2005 Jan;48(1):72-9
15617729
Synapse. 1994 Jan;16(1):36-44
8134899
Brain Res. 1996 May 20;721(1-2):196-203
8793101
Naunyn Schmiedebergs Arch Pharmacol. 1977 Mar;297(1):1-7
193046
Synapse. 1996 Apr;22(4):369-81
8867031
J Neurochem. 2002 Sep;82(5):1171-8
12358764
J Pharmacol Exp Ther. 1985 Nov;235(2):544-50
4057084
Brain Res. 2007 Jan 5;1127(1):90-8
17113052
J Pharmacol Exp Ther. 2004 Oct;311(1):80-91
15178698
J Neurochem. 2001 Feb;76(3):721-9
11158242
J Pharmacol Exp Ther. 1994 Jul;270(1):192-7
7913495
Br J Pharmacol. 2000 Nov;131(5):997-1003
11053222
J Pharmacol Exp Ther. 1987 May;241(2):443-7
3572804
Anal Biochem. 1976 May 7;72:248-54
942051
Eur J Neurosci. 2006 Jul;24(1):116-34
16882012
Neuropharmacology. 2003 Sep;45(3):334-44
12871651
Brain Res. 2000 Jun 9;867(1-2):157-64
10837809
Neurochem Res. 1988 Apr;13(4):305-9
2455873
Psychopharmacology (Berl). 1989;97(2):243-52
2471221
Brain Res. 1989 May 8;486(2):357-63
2471575
Neurosignals. 2004 May-Jun;13(3):114-21
15067198
Eur J Pharmacol. 1989 Jan 24;160(1):23-30
2714362
Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8
2899326
J Neurosci. 2006 Jan 18;26(3):723-30
16421292
J Pharmacol Exp Ther. 2000 Oct;295(1):58-66
10991961
Eur J Neurosci. 2006 Jul;24(1):188-96
16882016
Eur J Pharmacol. 1988 Aug 9;153(1):1-9
2905662
Eur J Neurosci. 2002 Jun;15(11):1810-8
12081661
Nature. 1990 Sep 6;347(6288):72-6
2144334
Ann N Y Acad Sci. 1992;668:165-72
1361111
J Chem Neuroanat. 2005 Jul;30(1):34-44
15975762
Brain Res. 1985 Dec 9;358(1-2):70-6
4075132
Psychopharmacology (Berl). 2007 Feb;190(3):269-319
16896961
Mol Psychiatry. 2003 Jan;8(1):50-9, 9
12556908
Nature. 2005 Jul 7;436(7047):103-7
16001069
Neuroreport. 1999 Mar 17;10(4):697-702
10208533
Neuroscience. 1991;45(1):81-93
1754070
J Biol Chem. 1988 Feb 5;263(4):1719-25
3276675
Neurochem Res. 2002 Mar;27(3):253-61
11958525
J Pharmacol Exp Ther. 1990 Nov;255(2):775-80
2147039
Neurosci Lett. 2001 Jan 26;298(1):1-4
11154821
J Physiol. 1994 Jan 1;474(1):119-29
8014889
Neuropharmacology. 2006 Jun;50(8):1030-40
16580026
Neuroscience. 2002;111(1):177-87
11955721
Eur J Neurosci. 2005 Mar;21(5):1145-54
15813924
Proc Natl Acad Sci U S A. 1988 Aug;85(15):5409-13
3399498
Brain Res. 1994 Dec 5;665(2):237-44
7895059
Brain Res Bull. 1997;42(3):211-9
8995332
Brain Res. 2001 Jun 29;905(1-2):120-6
11423086
Brain Res. 2006 Apr 26;1085(1):77-86
16574078
Brain Res. 2003 Nov 21;991(1-2):222-31
14575895
Psychopharmacology (Berl). 2005 Oct;182(2):297-304
16010538
Eur J Pharmacol. 2003 Jan 1;458(1-2):111-8
12498914
J Neurosci. 2001 Mar 1;21(5):1452-63
11222635
Endocrinology. 2000 Oct;141(10):3623-9
11014216
J Pharmacol Exp Ther. 1984 May;229(2):487-92
6201607
Neuropsychopharmacology. 2005 May;30(5):871-9
15637639
Eur J Pharmacol. 1989 Feb 7;160(3):409-12
2565819
Brain Res. 1987 Feb 10;403(1):147-50
3828807
Neuroscience. 2000;98(3):485-92
10869842
Neurosci Lett. 2003 Sep 11;348(2):61-4
12902018
Neurosci Lett. 1988 Nov 22;94(1-2):93-8
3071750
Neuropsychopharmacology. 2007 Feb;32(2):450-7
17091130
Biochem Pharmacol. 1985 Nov 15;34(22):4065-6
4062976
Neuropsychopharmacology. 2007 Jan;32(1):35-42
16710311
Neurochem Res. 2004 Sep;29(9):1779-92
15453274
Peptides. 2000 Nov;21(11):1751-3
11090931